Silvia Bonfiglio

Milan, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker.

ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker.

Journal: Leukemia
Published: December 20, 2024

Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL.

Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL.

Journal: HemaSphere
Published: July 11, 2024

Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma.

Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma.

Journal: Cancer research
Published: February 02, 2023

Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY.

Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY.

Journal: Leukemia
Published: January 12, 2023

Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY.

Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY.

Journal: Leukemia
Published: October 11, 2022

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib.

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib.

Journal: Blood advances
Published: August 24, 2022

Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells.

Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells.

Journal: Gut
Published: June 14, 2022

Genetic determinants of type 1 diabetes in individuals with weak evidence of islet autoimmunity at disease onset.

Genetic determinants of type 1 diabetes in individuals with weak evidence of islet autoimmunity at disease onset.

Journal: Diabetologia
Published: March 18, 2022

High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL.

High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL.

Journal: Blood advances
Published: November 23, 2021

Burden of rare coding variants in an Italian cohort of familial multiple sclerosis.

Burden of rare coding variants in an Italian cohort of familial multiple sclerosis.

Journal: Journal of neuroimmunology
Published: April 19, 2021

A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib.

A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib.

Journal: Leukemia & lymphoma
Published: March 05, 2021

Identification of differential DNA methylation associated with multiple sclerosis: A family-based study.

Identification of differential DNA methylation associated with multiple sclerosis: A family-based study.

Journal: Journal of neuroimmunology
Published: February 09, 2021
Showing 1-12 of 27

Last Updated: 09/26/2026